SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.51 HKD | 0.00% |
|
-5.56% | -21.54% |
| Sales 2023 | 1.86B 257M 2.01B | Sales 2024 * | 2.73B 377M 2.96B | Capitalization | 4.38B 604M 4.73B |
|---|---|---|---|---|---|
| Net income 2023 | -54M -7.46M -58.41M | Net income 2024 * | 107M 14.78M 116M | EV / Sales 2023 | 2.96 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 1.6 x |
| P/E ratio 2023 |
-114
x | P/E ratio 2024 * |
47.1
x | Employees | 2,872 |
| Yield 2023 * |
8.49% | Yield 2024 * |
10.6% | Free-Float | 44.97% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.92% | ||
| Current month | -3.77% | ||
| 1 month | -10.53% | ||
| 3 months | -10.53% | ||
| 6 months | -16.39% | ||
| Current year | -21.54% |
1 week
0.50
0.53
1 month
0.500.59
Current year
0.490.66
1 year
0.490.84
3 years
0.493.95
5 years
0.493.95
10 years
0.496.68
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Cheng Guo
FOU | Founder | 60 | 00-12-31 |
Gui Li Miao
DFI | Director of Finance/CFO | 50 | - |
Zhong Xin Jia
COO | Chief Operating Officer | 65 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Sheng Che
FOU | Founder | 63 | 00-12-31 |
Wei Cheng Guo
FOU | Founder | 60 | 00-12-31 |
Jiong Long Zhang
CIO | Chief Investment Officer | 62 | 06-05-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.42% | 4 M€ | -27.92% | ||
| 0.01% | 117 M€ | -1.38% | - | |
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.51 | 0.00% | 6 486 000 |
| 24-04-18 | 0.51 | 0.00% | 5,889,000 |
| 24-04-17 | 0.51 | +2.00% | 7,390,000 |
| 24-04-16 | 0.5 | -3.85% | 8,387,000 |
| 24-04-15 | 0.52 | 0.00% | 4,996,000 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT
More quotes
Sihuan Pharmaceutical Holdings Group Ltd is a holding company mainly engaged in pharmaceutical manufacturing business. The Company operates three segments. Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetics comprehensive solutions. Innovative Medicine and Other Medicine segment is engaged in the research and development of innovative drugs in the fields of digestion, oncology, non-alcoholic hepatitis, diabetes and complications. The Company also operates Generic Medicine segment.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.51
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.54% | 604M | |
| +27.97% | 672B | |
| +23.61% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.28% | 211B | |
| -0.38% | 203B | |
| -9.98% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 460 Stock
